Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok et al. · PI Bristol-Myers Squibb

Primary endpoint

Progression Free Survival (PFS)

Population

Unresectable or Metastatic Melanoma; n=945

doi:10.1056/NEJMoa1709684

Historical

Current

Future

3 noemes

Historical

1 noeme

Published findings from this trial. Vote whether the expert body still believes each noeme stands given current evidence.

The CheckMate-067 trial's stated primary conclusion — Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs. either monotherapy. — replicates in independent cohorts.

oncology

Current

1 noeme

Noemes tracking active replication, subgroup analysis, or long-term follow-up. Vote on the likelihood the original effect holds.

Recent follow-up analyses of CheckMate-067 are confirming the original effect size in real-world data.

oncology

Future

1 noeme

Open forecast horizons tied to this trial. Vote your probability that each resolves TRUE by the declared horizon.

By 2028, 10-year survival data from CheckMate-067 will show a plateau ≥40% in the combination arm.

oncology

71%

Semantically related trials

Nearest trials by noeme-centroid cosine distance. Lower = closer.

NCT02578680

0.1668

· 3 claims

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

NCT03036488

0.1895

· 3 claims

Pembrolizumab for Early Triple-Negative Breast Cancer

NCT00829166

0.2148

· 3 claims

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

NCT01958021

0.2197

· 3 claims

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

NCT01035255

0.2546

· 3 claims

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

NCT02140554

0.2563

· 3 claims

A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease